|Series A, 1/2013 |
AshHill Pharmaceutical Investments
Heart Metabolics Limited, a London, UK-based developer of a drug to treat heart failure for hypertrophic cardiomyopathy patients. Founded by Professor Michael Frenneaux and Dr. Houman Ashrafian, the company recently (June 2012) obtained orphan designation from the FDA for the use of perhexiline as first line treatment for moderate-to-severe heart failure due to HCM. It has also in-licensed a new chemical entity drug candidate from The University of Adelaide (Australia) for the treatment of heart failure.